Page last updated: 2024-11-04

sulfasalazine and Deficiency, IgG

sulfasalazine has been researched along with Deficiency, IgG in 2 studies

Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.

Research Excerpts

ExcerptRelevanceReference
"Three per cent developed selective IgA deficiency between 8 and 20 weeks after starting SASP."1.28Immunodeficiencies associated with sulphasalazine therapy in inflammatory arthritis. ( Bacon, PA; Farr, M; Kitas, GD; Tunn, EJ, 1991)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19901 (50.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Farr, M1
Kitas, GD1
Tunn, EJ1
Bacon, PA1
Leickly, FE1
Buckley, RH1

Other Studies

2 other studies available for sulfasalazine and Deficiency, IgG

ArticleYear
Immunodeficiencies associated with sulphasalazine therapy in inflammatory arthritis.
    British journal of rheumatology, 1991, Volume: 30, Issue:6

    Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Dysgammaglobulinemia; Female; Humans; IgA Deficiency

1991
Development of IgA and IgG2 subclass deficiency after sulfasalazine therapy.
    The Journal of pediatrics, 1986, Volume: 108, Issue:3

    Topics: Child; Colitis, Ulcerative; Humans; IgA Deficiency; IgG Deficiency; Immunoglobulin M; Male; Sulfasal

1986